Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes

Diabetic retinopathy (DR) is the leading cause of blindness in developing countries, especially in the working-age population.1 Diabetic macular edema (DME) is the most common cause of vision loss of DR, occurring in up to 12% of patients with type 1 and 28% of patients with type 2 diabetes .2,3 Thus, the treatment of DME remains one of the main challenges for the ophthalmological community.DME occurs from leakage of plasma into the central retina resulting in excess of interstitial fluid and thickening of the retina.4,5 The excess of interstitial fluid in the macula results in stretching and

Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye - April 19, 2018 Category: Opthalmology Authors: Gabriel Costa de Andrade, MD Source Type: research